Skip to main content

Table 1 Baseline characteristics

From: Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project

  SCD individualsn = 481
No. (%) with clinical progression 70 (15%)
 Progression to MCI 49 (10%)
 Progression to AD dementia 10 (2%)
 Progression to non-AD dementia 11 (2%)
Age 62 ± 9
Gender, no. (%) females 211 (44%)
MMSE 28 ± 1.6
Follow-up duration 3 ± 2
Medial temporal lobe atrophy 0.4 ± 0.5
Global cortical atrophy 0.4 ± 0.6
Hippocampal volume (cm3) 7.2 ± 1
Normalized whole brain volume (cm3) 1453 ± 100
Amyloid β1–42 879 ± 260
Total Tau 298 ± 196
p-tau 49 ± 22
  1. Data are mean ± standard deviation, unless otherwise specified. MMSE mini-mental state examination, MRI magnetic resonance imaging, CSF cerebrospinal fluid